ConcertAI’s TeraRecon Showcases New Clinical and AI Solutions Designed to Enhance Treatment Planning for Structural Heart Patients at TCT 2023

ConcertAI’s TeraRecon, a leader in advanced visualization and artificial intelligence (AI) for medical imaging, will showcase its latest innovations and cardiology solutions designed to strengthen clinical confidence, build efficiency throughout the care pathway, and improve cardiac care experiences at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco this week.

Innovation in the Intuition™ solution gives physicians the edge to deliver precise and timely diagnostic interpretations by semi-automating complex image post-processing through tailored advanced clinical workflows. Because it is designed to deliver clinical decision support throughout the enterprise, including radiology, cardiology, neurology, oncology, and vascular surgery, Intuition also enables cross-department consolidation and can eliminate redundant solutions.

The latest version of Intuition, 4.7, adds robust cardiovascular AV functionality through a dedicated Left Atrial Appendage (LAA) workflow, updated Transcatheter Mitral Valve Repair (TMVR) workflow, and various enhancements to streamline cardiac coronary imaging and pre-op planning. These tools provide interventionalists with enhanced visualizations, semi-automated measurements, flexible interaction capabilities, and interoperability designed to streamline procedural planning and eliminate the need for multiple AV solutions.

Cardiology Suite, powered with partners Us2.ai and Coreline Soft, aims to fully automate the analysis and interpretation of echocardiograms and chest CT exams to assess, monitor, and provide insights to help support clinicians in treatment decisions for cardiac patients. Through automated measurements and reports, these AI solutions can help reduce image interpretation times and improve workflows while maintaining accuracy and reducing variability between operators and devices.

Cardiology Suite applications on the Eureka Clinical AI platform are FDA and CE-cleared with additional regional clearances. For full availability of each algorithm, please reach out to TeraRecon. Learn more about the Eureka Clinical AI platform capabilities at www.terarecon.com/artificial-intelligence.

“We are excited to be kicking off the controlled release of FEops HEARTguide™ software in combination with our market leading AV software, Intuition, to enable physicians to better plan and, therefore, better treat patients with LAA closure devices,” said Dan McSweeney, President of TeraRecon. “With the addition of FEops’ advanced Digital Twin clinical AI solution, we are poised to provide clinicians with an unparalleled tool streamlining CT-based preoperative planning for structural heart interventions, leading to more informed decision-making.”

FEops HEARTguide is a unique cloud-based procedure planning solution in the structural heart, based on Digital Twin technologies. With the LAA occlusion workflow, FEops HEARTguide enables U.S. physicians to virtually model different implant positions and sizes of FDA approved LAA devices, aiding physicians in the selection of the optimal size and position for a specific patient. Established clinical evidence from the randomized controlled PREDICT-LAA trial has shown that FEops’ Digital Twin-based planning for LAA closure results in improved procedure efficiency and outcomes as compared to standard CT based planning.

Stop by booth #2241 on Tuesday, October 24, 2-4pm, or Wednesday, October 25, 2-4pm, to meet our newest collaborator and see their state-of-the-art FEops HEARTguide solution, the latest AI-powered device simulation to support preoperative planning procedures for LAA occlusion.

TeraRecon will also be hosting two physician-led presentations in booth #2241 during TCT 2023:

Tuesday, October 24, 12:30 PM – Dr. Serge C. Harb, MD, FACC will be presenting Cardiac CT in Planning Structural Interventions: A Case-based and Hands-on Approach.
Wednesday, October 25, 12:30 PM – Dr. Devi Nair, MD, FACC, FHRS will be presenting Novel Device Simulation for CT-based Preoperative Planning in LAA Closure.

Schedule a meeting or demo to learn more about these new technologies at #TCT23:
https://www.terarecon.com/tct-2023-meeting-request-0

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.
AppliedVR Co-founder and President Josh Sackman, "We're committed to developing a significant body of scientific evidence that demonstrates how our RelieVRx program, which is rooted in self-regulation, cognitive behavioral therapy skills and mindfulness, engages the brain and can impact the experience of pain. While we know there can be a strong placebo effect, this feasibility study showed that only the active RelieVRx treatment created changes at a physiological and brain activity level, creating a strong foundation for future research."
Researchers and clinicians from Emory Winship Cancer Institute collaborated to test their prostate cancer population notes Prevencio.
First patients treated with H-Guard at the National Institute for Health and Care Research Manchester Clinical Research Facility. MHRA approves continuation of Invizius's first-in-human clinical study following a prearranged two-patient safety and performance review. Study is investigating safety and tolerability of H-Guard®, a second generation complement regulator, to address serious immune system-driven complications of dialysis.

By using this website you agree to accept Medical Device News Magazine Privacy Policy